0001828185-24-000093.txt : 20241125 0001828185-24-000093.hdr.sgml : 20241125 20241125160618 ACCESSION NUMBER: 0001828185-24-000093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241125 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241125 DATE AS OF CHANGE: 20241125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Barinthus Biotherapeutics plc. CENTRAL INDEX KEY: 0001828185 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40367 FILM NUMBER: 241495923 BUSINESS ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF BUSINESS PHONE: 44 (0) 1865 818808 MAIL ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech plc DATE OF NAME CHANGE: 20210407 FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech Ltd DATE OF NAME CHANGE: 20201014 8-K 1 brns-20241125.htm 8-K brns-20241125
false000182818500-000000000018281852024-11-252024-11-250001828185brns:AmericanDepositarySharesMember2024-11-252024-11-250001828185us-gaap:CommonStockMember2024-11-252024-11-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 25, 2024
BARINTHUS BIOTHERAPEUTICS PLC
(Exact name of registrant as specified in its charter)
England and Wales001-40367Not Applicable
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
Barinthus Biotherapeutics plc
Unit 6-10, Zeus Building Rutherford Avenue,
Harwell, Didcot, OX11 0DF
United Kingdom
(Address of principal executive offices, including zip code)
+44 (0) 1865 818 808
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrade Symbol(s)
Name of each exchange on which
registered
American Depositary SharesBRNSThe Nasdaq Global Market
Ordinary shares, nominal value £0.000025 per share*
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.


Item 8.01. Other Events.

On November 25, 2024, the Company issued a press release titled “Barinthus Bio Promotes SNAP-TI Co-Inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer.” The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Barinthus Biotherapeutics plc
Date: November 25, 2024By:/s/ William Enright
William Enright
Chief Executive Officer

 EX-99.1 2 brns-20241125xexx991.htm EX-99.1 Document

a1.jpg
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

OXFORD, United Kingdom and GERMANTOWN, MD, United States, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio’s CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.

“Dr. Pelletier’s strong vision and leadership have resulted in a robust preclinical pipeline of promising leads for targeting autoimmune and other inflammatory diseases. She has played a pivotal role in the new company structure and across all R&D activities,” said Bill Enright, Chief Executive Officer of Barinthus Bio. “We’re very grateful for Dr. Pelletier’s contributions to our growing pipeline and expect a smooth transition with the appointment of Dr. Lynn. As co-inventor of the SNAP-TI technology, he is a natural successor into the CSO role.”

Dr. Pelletier will remain with the Company until the transition of responsibilities to Dr. Lynn is complete.

“This is an incredibly exciting time for Barinthus Bio. We have achieved functional cures with VTP-300 in patients with chronic hepatitis B, and VTP-1000, our first product candidate developed using the SNAP-TI technology, recently entered the clinic in a Phase 1 trial for individuals with celiac disease,” said Dr. Lynn. “Dr. Pelletier has put Barinthus in a strong position with a compelling pipeline of assets, including our first program in the autoimmune disease space, and I look forward to building on this momentum while also exploring new opportunities to build value.”

Dr. Lynn is a seasoned biotech innovator and executive with over 15 years of experience leading immunotherapeutic R&D from discovery through early development. Prior to joining the Company, Dr. Lynn led Avidea Technologies, Inc. as CEO and Founder from its launch at Johns Hopkins FastForward in 2017 through to its acquisition by Barinthus Bio in 2021. Dr. Lynn holds a M.D. from the Johns Hopkins University School of Medicine (US), as well as a D.Phil. from the University of Oxford.



About Barinthus Bio
Barinthus Biotherapeutics (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in infectious diseases and autoimmunity, including: VTP-300, that utilizing its ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection and VTP-1000, utilizing our SNAP-Tolerance Immunotherapy (SNAP-TI) platform and is designed to treat people with celiac disease. Barinthus Bio is also conducting a Phase 1 clinical trial for VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s differentiated technology platforms and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with chronic infectious diseases and autoimmunity. For more information, visit www.barinthusbio.com.



Barinthus Bio’s Forward Looking Statements
This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,” “expect,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding Barinthus Bio’s future expectations, plans and prospects, the terms and timing of the anticipated officer transition. Any forward-looking statements in this press release are based on Barinthus Bio management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of Barinthus Bio’s pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary, interim or final data or initiation of its clinical trials may be delayed, the risk that interim or topline data may not reflect final data or results, Barinthus Bio’s ability to execute on its strategy, regulatory developments, the risk that Barinthus Bio may not achieve the anticipated benefits of its pipeline prioritization and corporate restructuring, Barinthus Bio’s ability to fund its operations and access capital, Barinthus Bio’s cash runway, including the risk that its estimate of its cash runway may be incorrect, global economic uncertainty, including disruptions in the banking industry, the conflicts in Ukraine, Israel and Gaza, and other risks identified in Barinthus Bio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Barinthus Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Barinthus Bio expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.



IR contacts:
Christopher M. Calabrese 
Managing Director 
LifeSci Advisors
+1 917-680-5608
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors
+1 617-283-2856
kgardner@lifesciadvisors.com

Media contact:
Audra Friis
Sam Brown, Inc.
+1 917-519-9577
audrafriis@sambrown.com

Company contact:
Jonothan Blackbourn
IR & PR Manager
Barinthus Bio
ir@barinthusbio.com

 EX-101.SCH 3 brns-20241125.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 brns-20241125_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 brns-20241125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Country Entity Address, Country Document Period End Date Document Period End Date Ordinary Shares Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Statement [Table] Statement [Table] Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code American Depositary Shares American Depositary Shares[Member] American Depositary Shares Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Registrant Name Entity Registrant Name EX-101.PRE 6 brns-20241125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 a1.jpg begin 644 a1.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
Nov. 25, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 25, 2024
Entity Registrant Name BARINTHUS BIOTHERAPEUTICS PLC
Entity Incorporation, State or Country Code X0
Entity File Number 001-40367
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One Barinthus Biotherapeutics plc
Entity Address, Address Line Two Unit 6-10
Entity Address, Address Line Three Zeus Building Rutherford Avenue
Entity Address, City or Town Harwell, Didcot
Entity Address, Postal Zip Code OX11 0DF
Entity Address, Country GB
City Area Code +44 (0)
Local Phone Number 1865 818 808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001828185
American Depositary Shares  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares
Trading Symbol BRNS
Security Exchange Name NASDAQ
Ordinary Shares  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.000025 per share*
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 3 25 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.barinthusbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports brns-20241125.htm brns-20241125.xsd brns-20241125_def.xml brns-20241125_lab.xml brns-20241125_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "brns-20241125.htm": { "nsprefix": "brns", "nsuri": "http://www.barinthusbio.com/20241125", "dts": { "inline": { "local": [ "brns-20241125.htm" ] }, "schema": { "local": [ "brns-20241125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "brns-20241125_def.xml" ] }, "labelLink": { "local": [ "brns-20241125_lab.xml" ] }, "presentationLink": { "local": [ "brns-20241125_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 32, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.barinthusbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "brns-20241125.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "brns-20241125.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "brns_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.barinthusbio.com/20241125", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "American Depositary Shares", "label": "American Depositary Shares[Member]", "documentation": "American Depositary Shares" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Three", "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.barinthusbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001828185-24-000093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001828185-24-000093-xbrl.zip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end XML 19 brns-20241125_htm.xml IDEA: XBRL DOCUMENT 0001828185 2024-11-25 2024-11-25 0001828185 brns:AmericanDepositarySharesMember 2024-11-25 2024-11-25 0001828185 us-gaap:CommonStockMember 2024-11-25 2024-11-25 false 0001828185 00-0000000 8-K 2024-11-25 BARINTHUS BIOTHERAPEUTICS PLC X0 001-40367 Barinthus Biotherapeutics plc Unit 6-10 Zeus Building Rutherford Avenue Harwell, Didcot OX11 0DF GB +44 (0) 1865 818 808 false false false false American Depositary Shares BRNS NASDAQ Ordinary shares, nominal value £0.000025 per share* true false